Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...

Our productive engagement with the European Medicines Agency (EMA) highlighted by confirmation of eligibility to submit for a conditional ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...